Next Article in Journal
Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
Previous Article in Journal
The Role of Adenovirus in Cancer Therapy
 
 
Correction published on 17 January 2021, see Cancers 2021, 13(2), 329.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Biological Aging Marker p16INK4a in T Cells and Breast Cancer Risk

1
Departments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
Departments of Family Medicine and Population Health, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA
3
Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA
4
Department of Surgery, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(11), 3122; https://doi.org/10.3390/cancers12113122
Submission received: 21 September 2020 / Revised: 13 October 2020 / Accepted: 19 October 2020 / Published: 26 October 2020
(This article belongs to the Section Cancer Epidemiology and Prevention)

Abstract

:

Simple Summary

The association between cellular senescence, a hallmark of biological aging, and cancer risk has not been examined in population-based studies. To fill the gap, in this study, we assessed the relationship between p16INK4a mRNA expression in T cells, a marker of cellular senescence, with breast cancer risk and selected sociodemographic and lifestyle variables. Overall, we discovered that higher p16INK4a mRNA expression in T cells was associated with an increased risk of breast cancer. Also, we found that p16INK4a mRNA expression in T differed by age, race, family history of cancer, marital status, annual income, and smoking status. The results of this study provide evidence that cellular senescence plays a role in breast cancer development. Furthermore, our results also suggest that social demographics may modify cellular senescence and biological aging.

Abstract

Prior research has demonstrated that altered telomere length, a well-known marker for biological aging, is associated with various types of human cancer. However, whether such association extends to additional hallmarks of biological aging, including cellular senescence, has not been determined yet. In this two-stage study, we assessed the association between p16INK4a mRNA expression in T cells, a marker of cellular senescence, and breast cancer risk. The discovery stage included 352 breast cancer patients and 324 healthy controls. p16INK4a mRNA expression was significantly higher in individuals who were older, Black, and had family history of cancer than their counterparts in both cases and controls. p16INK4a mRNA expression also differed by marital status, annual income, and smoking status in cases. In the discovery stage, we found that increased p16INK4a mRNA expression was associated with 1.40-fold increased risk of breast cancer (OR = 1.40; 95%CI: 1.21, 1.68; p < 0.001). A marginally significant association was further observed in the validation stage with 47 cases and 48 controls using pre-diagnostic samples (OR = 1.28; 95%CI: 0.98, 2.97; p = 0.053). In addition, we found that p16INK4a mRNA expression was higher in tumors with selected aggressive characteristics (e.g., poorly differentiated and large tumors) than their counterparts. In summary, our results demonstrate that higher p16INK4a mRNA expression in T cells is a risk factor for breast cancer and further support the role of biological aging in the etiology of breast cancer development. Novelty and Impact Statements: The results from this study provide evidence that cellular senescence, a process of biological aging, plays a role in breast cancer etiology. In addition, our results also support that social demographics may modify cellular senescence and biological aging.

1. Introduction

Elevated production of stress hormones due to stress exposure can increase DNA damage [1,2]. Excessive DNA damage can initiate cellular senescence and further accelerate biological aging [3]. The cell cycle inhibitor p16INK4a is a well-known biomarker for cellular senescence. The expression of p16INK4a due to stress exposure and DNA damage can prevent the replication of cells with severe DNA damage [4]. However, persistent cellular senescence via heightened p16INK4a can become detrimental because certain senescent cells may release pro-inflammatory factors to promote inflammation, damage nearby cells and tissues, further accelerate biological aging, and consequently increase the risk of age-related diseases [3,5]. Intriguingly, studies in mice have shown that eliminating p16INK4a-positive cells not only reduced cellular aging but also hindered tumor growth and reduced tumor progression [6]. This suggests that senescent cells play an essential role in age-related deterioration and tumorigenesis. Furthermore, the expression of p16INK4a is not an epiphenomenon of aging but appears to play a causal role in the age-associated replicative decline of several tissues, including T-cells [7].
p16 INK4a mRNA expression, which is not detected in young cells, can result in senescent cells that remain indefinitely within tissues [8,9,10,11], and it may potently be activated by stress. For instance, in a recent study, significant increase in p16INK4a mRNA expression in blood was observed in relation to an increase in chronic stress exposure and daily stress appraisals [12], suggesting that p16INK4a mRNA, a biomarker of cellular senescence, may be a mechanism by which exposure to stressful life events “get under the skin”. In addition, both extrinsic lifestyle factors, such as smoking and physical inactivity, and common chronic diseases and their treatments, such as with chronic HIV infection, induce p16INK4a expression, thereby promoting cellular senescence [13,14].
In relation to tumor development, loss of p16INK4a is one of the most frequent events in human tumors and allows precancerous lesions to bypass senescence. On the other hand, lasting p16INK4a expression drives cells to enter senescence and thereby aging. Thus, precise regulation of p16INK4a is essential to tissue homeostasis, maintaining a coordinated balance between tumor suppression and aging [15].To date, the role of cell senescence and p16INK4a expression in the development of breast cancer has not been evaluated in molecular epidemiologic studies. To fill the gap, we conducted a two-stage study (discovery and validation) to assess the relationship between p16INK4a mRNA expression in T cells and breast cancer risk. In the discovery stage, we compared p16INK4a mRNA expression in T cells obtained from breast cancer cases and healthy controls. In the validation stage, we validated the association in a nested breast cancer case–control study using pre-diagnostic peripheral blood mononuclear cells (PBMCs).

2. Materials and Methods

2.1. Study Population

The study participants in the discovery stage were selected from an ongoing breast cancer case–control study beginning in 2012. Participants were patients at The University of Texas M. D. Anderson Cancer Center (Houston, TX, USA) with newly diagnosed (defined by the presence of malignant breast epithelial cells) and histologically confirmed (by microscopic analysis and molecular subtype) breast cancer. Blood samples were drawn prior to any cancer treatment. Controls were identified largely from female residents of Harris County using random digit dialing. Written informed consent was obtained from each study participant. To assess the relationship between p16INK4a mRNA expression in T cells and breast cancer risk, we selected 400 cases consecutively recruited since the start of 2015. We reached the goal around June of 2016. During the same period, we also recruited 362 controls. Those cases and controls were included in this study. Self-reported ethnic background was used to define race and ethnicity. The in-person, interviewer-administered questionnaires were conducted at the time of enrollment, which included sociodemographic, reproductive, comorbidities, and other measures. Definitions used in the National Health Interview Survey (NHIS by CDC) were applied to define demographic variables, such as smoking and drinking status and physical activity in the past 12 months. All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by Institutional Review Board at M D Anderson Cancer Center.
To validate the results, we ascertained specimens and data from an independent sample of 50 incident breast cancer cases and 50 controls from Mano-A-Mano, the Mexican American Cohort study (MAC). A detailed description of breast cancer cases in the MAC study has been described previously [16,17]. By 1 December 2017, with a median follow-up time of 8.2 years, a total of 126 newly diagnosed breast cancers were identified. Among them, 109 were validated through the Texas Cancer Registry and had blood samples that were collected at baseline. The case selection was based on the availability of PBMC samples in the biorepository. We only selected the cases whose samples were collected at least one year before their cancer diagnosis. The cases and controls were matched on age at recruitment (±2 years) and date of biospecimen collection (±1 year). The study protocol was approved by the Institutional Review Board at M. D. Anderson Cancer Center.

2.2. P16INK4a mRNA Expression Analysis

EasySep™ Human T Cell Isolation Kit (Stemcell, Cambridge, MA, USA; Cat#17951) was used to isolate T cells from frozen peripheral blood mononuclear cells. Total RNA was isolated from the isolated T cells by using Trizol reagent (ThermoFisher, Carlsbad, CA, USA; Cat#15596026). RT reactions were conducted using the QuantiTect Reverse Transcription kit (QIAGEN, Germantown, MD, USA; Cat#205311). Expression of p16INK4a mRNA was quantified by qPCR (standard curve method) using at least two independent RT reactions for each sample and the QuantiNova SYBR® Green PCR Kit (QIAGEN, Germantown, MD, USA; Cat#208052). The following primers were used: (forward) CCAACGCACCGAATAGTTACG, (reverse) GCGCTGCCCATCATCATG. Additionally, 18 s expression was measured as a mean to normalize p16INK4a levels. The 18 s primers were (forward) TCAACTTTCGATGGTAGTCGCCGT, (reverse) TCCTTGGATGTGGTAGCCGTTTCT. Using this method, 48 cases and 38 controls in the discovery stage, and 3 cases and 2 controls in the validation stage failed analysis due to either insufficient nucleic acid yield, poor quality RNA, or replicate failure. They were excluded from further analysis. We compared the distribution of social demographics, health behaviors, and tumor characteristics between the excluded and included samples. No statistically significant difference was observed in both cases and controls.

2.3. Statistical Analysis

We used the statistical software package SAS version 9.4 (SAS, Cary, NC, USA) for all analyses. Because p16 INK4a mRNA expression increases exponentially with age, results were logarithmically transformed. First, we evaluated whether p16 INK4a expression and selected social demographics (age, race, education, marital, income, BMI, and family history of cancer) and healthy behaviors (cigarette smoking, alcohol drinking, physical activity, and sitting time) differed between breast cancer patients and healthy controls. The Student t test was used for two-level dichotomous variables, and analysis of variance was used for variables with more than two levels. Next, we used linear regression analysis to evaluate whether mean p16 INK4a expression differed across categories in each of the selected demographic variables of the cases and controls and tumor characteristics (estrogen receptor (ER) status, tumor stage, grade, and size) of the cases. Age was adjusted in the analysis. We also compared case–control difference in p16 INK4a expression in each category of each selected demographic variable. For the association between p16 INK4a expression and breast cancer risk, we used unconditional multivariate logistic regression to estimate odds ratios (ORs) and 95% Confidence Intervals (CIs). The analysis was adjusted for potential confounders. p16 INK4a expression was treated as a continuous variable or as a categorical variable in dichotomous and quartile analyses. In dichotomized analysis, p16 INK4a expression was designated as “high” or “low” using the controls’ 75% levels of p16 INK4a expression as cutoffs. In quartile analysis, p16 INK4a expression was designated using the controls’ quartile levels of p16 INK4a expression as cutoffs. In the validation analysis, p16 INK4a expression was treated as a continuous variable. We applied similar multivariate logistic regression analysis to assess relationships between p16 INK4a expression and breast cancer risk.

3. Results

After excluding samples that failed in p16 INK4a expression analysis (48 cases and 38 controls), a total of 352 breast cancer cases and 324 healthy controls was included in the analysis (Table 1). In terms of social demographics, no significant differences between cases and controls were observed for race, marital status, and BMI category. Compared to the controls, cases were older (56.82% ≥51 years vs. 46.30% ≥51 years) (p < 0.006) and a greater percentage had a family history of cancer (18.47% vs. 8.95, p < 0.001). A borderline difference between cases and controls was observed for education (p = 0.089) and income (p = 0.058), with cases trending toward lower educational attainment and income. No significant differences were observed between the groups with respect to smoking status, alcohol use, physical activity, or time sitting. For tumor characteristics, 23.86% cases were estrogen receptor negative (ER-), 19.89% had stage III tumors, 23.58% had poorly differentiated tumors, and 21.31% had large tumors (≥2 cm). Overall, the cases had statistically significantly higher P16INK4a mRNA expression in T cells than the controls (4.58% vs. 3.27%, p < 0.0001).
Next, we assessed the relationship between p16INK4a mRNA expression and social demographics and lifestyle factors within the controls after adjusting age (Table 2). Compared to younger women (<51 years), older women (≥51 years) had higher p16INK4a mRNA expression (4.72 vs. 2.02, p < 0.001). Compared to White women, Black women had statistically significantly higher p16INK4a mRNA expression (3.79 vs. 3.08, p = 0.021). No statistical significance in p16INK4a mRNA expression was observed between Hispanic and White women. Compared to those with no family history of cancer, those with family history of cancer had higher p16INK4a mRNA expression (4.90 vs. 3.11, p < 0.001). Furthermore, no significant difference in p16INK4a mRNA expression was observed across education, marital status, income, BMI category, smoking status, alcohol status, physical activity, and sitting time. The same analysis was also applied to the cases. Similarly, older cases had higher p16INK4a mRNA expression than younger cases (5.79 vs. 2.99, p < 0.001), Black cases had statistically significantly higher p16INK4a mRNA expression than their White counterparts (5.18 vs. 4.22, p = 0.013), and cases with family history of cancer had higher p16INK4a mRNA expression than those without (5.86 vs. 4.29, p < 0.001). Cases who were not married or living together had higher p16INK4a mRNA expression than those who were married or living together (4.92 vs. 4.27, p = 0.029). In addition, we found that cases with less than USD 50,000 annual income had higher p16INK4a mRNA expression than those with at least USD 50,000 annual income (4.93 vs. 4.25, p = 0.009). p16INK4a mRNA expression was also found diffed by smoking status. Compared to never smokers, current smokers had higher p16INK4a mRNA expression (5.21 vs. 4.33, p = 0.039). In addition, current drinker had marginally significant higher p16INK4a mRNA expression than never drinkers (4.96 vs. 4.29, p = 0.068). We also assessed the relationship between tumor characteristics and p16INK4a mRNA expression among cases. Higher p16INK4a mRNA expression was observed in cases with poorly differentiated tumors (p = 0.002) and larger (≥2 cm) tumors (p = 0.025) than their counterparts. Then, we assessed whether higher p16INK4a mRNA expression differed between cases and controls in each category of selected characteristics. As expected, the cases had statistically significantly higher p16INK4a mRNA expression than the controls in each category, except with family history of cancer (p = 0.280).
We then examined the association between higher p16INK4a mRNA expression in T cells and breast cancer risk (Table 3). If treated as a continuous variable, increased higher p16INK4a mRNA expression was associated with 1.40-fold increased risk of breast cancer after adjusting age, race, education, marital, income, BMI category, family history of cancer, smoking status, alcohol status, physical activity, and sitting time (OR = 1.40; 95%CI: 1.21, 1.68; p < 0.001). In dichotomized analysis, using the 75% levels of p16INK4a mRNA expression in controls as the cutoff point (4.76), those with higher p16INK4a mRNA expression had 1.81-fold increased risk of breast cancer (OR = 1.81; 95%CI: 1.29, 2.45; p < 0.001). In further quartile analysis, the risk association between increased p16INK4a mRNA expression and breast cancer risk was further validated. Compared to those who had the lowest (1st quartile) p16INK4a mRNA expression, those with highest (4th quartile) p16INK4a mRNA expression had 2.46-fold increased risk of breast cancer (OR = 2.46; 95%CI: 1.57, 4.04; p < 0.001). In addition, a significant trend of increasing risk of breast cancer was observed when p16INK4a mRNA expression increased (p < 0.001).
Finally, we attempted to confirm the observed significant association between p16INK4a mRNA expression and breast cancer risk in pre-diagnostic PBMCs (Table 4). The cases and controls were well-matched on age, parity, education level, birthplace, language acculturation, BMI category, smoking status, alcohol drinking, and physical activity. Compared to healthy controls (n = 48), incident breast cancer cases (n = 47) had statistically significant higher levels of p16INK4a mRNA expression (4.39 vs. 3.41, p = 0.037). In the univariate analysis, higher p16INK4a mRNA expression in PBMCs was associated with 1.29-fold increased risk of breast cancer (OR = 1.29; 95%CI: 1.02, 2.72, p = 0.047). In the multivariate analysis, higher p16INK4a mRNA expression was marginally associated with 1.28-fold increased risk of breast cancer (OR = 1.28; 95%CI: 0.98, 2.97; p = 0.053) after adjusting age, BMI category, smoking status, alcohol status, and physical activity.

4. Discussion

To date, no study has evaluated the association between p16INK4a mRNA expression in T cells and breast cancer risk. In the discovery phase using 48 breast cancer cases and 47 controls, we found that increased pre-treatment p16INK4a mRNA expression was associated with 1.40-fold increased risk of breast cancer (OR = 1.40; 95%CI: 1.21, 1.68; p < 0.001). A marginally significant association was further observed in the validation stage using pre-diagnostic blood samples from the Mano-A-Mano cohort, as increased p16INK4a mRNA expression was associated with 1.28-fold increased risk of breast cancer (OR = 1.28; 95%CI: 0.98, 2.97; p = 0.053). In addition, we found that p16INK4a mRNA expression differed by age, race, and family history of cancer in both case and control groups, and by marital status, annul income, and smoking status in the case group. In addition, we found that p16INK4a mRNA expression was higher in tumors with selected aggressive characteristics (e.g., poorly differentiated and large tumors) than their counterparts.
The significant association between age group and p16INK4a mRNA expression is expected since p16INK4a mRNA expression is a marker for cell senescence, which is associated with biological aging [15]. We observed that Black women had higher p16INK4a mRNA expression than White women in our study in both cases and controls. Though racial difference between Black and White women in telomere length, the best known marker of biological aging, has been reported previously [18,19,20,21], no study has reported the racial difference in p16INK4a mRNA expression. In telomere length, most of the studies have found that Black and/or Hispanic women had shorter telomere length than White women [18,19,21]. Furthermore, the rate of telomere shortening, which may reflect the cumulative burden of exposure to various chronic stressors over the life course, was found quicker in Black and/or Hispanic women than White women [18,19,21]. Those findings support the notion that exposure to adverse social conditions (e.g., racism) is associated with accelerated biological aging [22]. In fact, in the United States, compared to White women, Black and Hispanic women are more likely to exposure to higher levels of social adversity during their lifetime [23,24,25]. The cumulative exposure to higher life-course adversity among Black and Hispanic women may therefore increase the likelihood of accelerated biological aging and displaying aging phenotypes, cellular senescence with shortened telomere and elevated p16INK4a mRNA expression, and ultimately increase their risks of breast cancer, developing more aggressive breast tumor phenotypes, and shortened survival [26].
In support of this hypothesis, in this study, we found that breast cancer cases with less than USD 50,000 annual income had higher p16INK4a mRNA expression than those with at least USD 50,000 annually (p = 0.009). A similar trend was also observed for education, with lower education having higher p16INK4a mRNA expression, but the difference did not reach statistical significance. Interestingly, we also found p16INK4a mRNA expression was higher in breast cancer cases who were not married or living together than cases who were married or living together (p = 0.029). Social support is arguably the fundamental cause of health differentials. The mutual support from the family member and/or partner will provide a buffer that can help better weather adverse social conditions and reduce stress, which, consequently, may slow down the biological aging process. To date, only one study has assessed the relationship between social adversity, chronic stress, and p16INK4a mRNA expression [12], which shows that chronic stress exposure and daily stress appraisals were associated with increased p16INK4a mRNA expression. Our results may suggest that exposure to adverse social conditions is associated with accelerated biological aging, offering one mechanism through which adversity may increase the risk for age-related diseases, such as breast cancer.
We also observed that p16INK4a mRNA expression could be modified by cigarette smoking status. Our results are consistent with previous findings [13,27,28]. Liu et al. reported that dosage effect as p16INK4a expression in peripheral blood T-cells was associated with cumulative exposure as estimated by tobacco pack-years [13]. It has been reported that DNA damage from cigarette smoke induces senescence via the p16 pathway, and targeting p16-induced senescence could prevent cigarette smoking-induced emphysema in mice [27]. The study by Liu et al. also reported an inverse relationship between exercise and p16INK4a mRNA expression [13]. In our study, we found that those with medium or high levels of physical activity had lower p16INK4a mRNA expression in both case and control groups. However, none of the association reached statistical significance (p = 0.124 and 0.189, respectively). We also failed to observe the association between sitting time and p16INK4a mRNA expression. However, similar to Liu’s study, no significant relationship between obesity and p16INK4a mRNA expression was found. One interesting observation in our study is that the difference in p16INK4a mRNA expression by income level, marital status, and smoking status was more evident in breast cancer cases than controls. It is possible that there is not enough variation in those social demographics and healthy behaviors in our controls. It may also suggest that cancer diagnosis may have an influence. Thus, in the future, large prospective studies are needed to further clarify the relationship.
The higher levels of p16INK4a mRNA expression in both cases and controls with a family history of cancer than those without are intriguing. Learning that a family member has cancer is a stressful event because it may unavoidably lead to the speculation about whether they will also have cancer due to their shared genetic background [29,30]. Previous studies in breast cancer have shown that women with a family history of breast cancer have higher levels of cancer-specific distress than those without a family history [31,32]. A positive coping style can encourage good psychological adjustment and thereby alleviate the stress. On the other hand, a negative coping style can further exacerbate stress and consequently lead to harmful health impacts [33,34]. Unfortunately, the current study did not collect data on coping styles.
The relationship between higher p16INK4a mRNA expression and breast cancer risk is expected. As mentioned previously, the expression of p16INK4a is a protective mechanism to guard against excessive DNA damage and prevent damaged cells from proliferating and causing further transformation to malignancy [3,4]. However, persistently elevated p16INK4a mRNA expression may have a detrimental consequence. Specific senescent cells may secrete pro-inflammatory cytokines, growth factors, and matrix-remolding enzymes that can cause damage to nearby cells or tissues and further promote tumorigenesis [5,35]. Those resulting pro-inflammatory cytokines could summon inflammatory cells and promote growth and survival of nearly cells. In the case of breast carcinogenesis, if breast premalignant and/or tumor cells are nearby, those pro-inflammatory cytokines will contribute to the promotion and progression of breast tumor. In our study, the association between p16INK4a mRNA expression and breast cancer risk was weakened when using pre-diagnostic samples. This may be simply because of the smaller sample size which did not provide adequate statistical power for us to detect the association. It may also suggest that p16INK4a mRNA expression differs by the breast carcinogenesis process. It has been suggested that p16INK4a mRNA expression is increased in pre-malignant lesions but decreased after tumor development [36,37,38]. All pre-diagnosed samples from the breast cancer cases were obtained from at least one year prior to the date of disease diagnosis, but with a wide range of from 1 to 15 years. The sample size is too small to be further stratified by the duration between blood drawn and disease diagnosis. We also did not have the information in this study to determine when the pre-malignant lesions and tumors actually began to develop, thus, the variation of p16INK4a mRNA expression by breast carcinogenesis process cannot be accounted for in our analyses. Another possibility is the difference in biospecimens used in analyzing p16INK4a mRNA expression, T cells in the discovery study, and PBMC in the validation study. In addition to T cells, PBMCs contain other lymphocytes (e.g., B cells and NK cells). Though both T cells and PBMCs have been used in studying p16INK4a mRNA expression [12,13,14], it is possible that the relationship observed in T cells may be weakened in PBMCs.

5. Conclusions

In summary, we have demonstrated that increased p16INK4a mRNA expression in T cells is associated with increased risk of breast cancer. We also reported that p16INK4a mRNA expression differed by selected social demographics, healthy behaviors, and tumor characteristics. Due to the modest sample size, particularly in validation stage, our results need to be further validated in large prospective cohort studies. Yet, the results from this study lend a support to the assumption that chronic stress is associated with accelerated aging by inducing cellular senescence, consequently contributing to increased risk of breast cancer among women.

Author Contributions

Study design: J.S., R.S., W.-H.C. and H.Z.; molecular analysis: J.S. and R.S.; data analysis: J.S. and H.Z.; manuscript draft J.S., B.F.F., K.P.M., W.-H.C. and H.Z. All authors have read and agreed to the published version of the manuscript.

Funding

The study was supported by U01 CA179655 from NCI/NIH.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

Ethics approval All procedures performed in this study were approved by the Institutional Review Board at M D Anderson Cancer Center and in accordance with the ethical standards of 1964 Helsinki declaration and its later amendments or comparable ethical standards on 1 July 2012 (ethic code: PA12-0862), and all patients signed an informed consent form.

References

  1. Flint, M.S.; Baum, A.; Chambers, W.H.; Jenkins, F.J. Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones. Psychoneuroendocrinology 2007, 32, 470–479. [Google Scholar] [CrossRef] [PubMed]
  2. Hara, M.R.; Kovacs, J.J.; Whalen, E.J.; Rajagopal, S.; Strachan, R.T.; Grant, W.; Towers, A.J.; Williams, B.; Lam, C.M.; Xiao, K.; et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 2011, 477, 349–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Campisi, J. Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 2005, 120, 513–522. [Google Scholar] [CrossRef] [PubMed]
  4. Campisi, J.; di Fagagna, F.D.A. Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8, 729–740. [Google Scholar] [CrossRef] [PubMed]
  5. Coppe, J.P.; Desprez, P.Y.; Krtolica, A.; Campisi, J. The senescence-associated secretory phenotype: The dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5, 99–118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Baker, D.J.; Wijshake, T.; Tchkonia, T.; LeBrasseur, N.K.; Childs, B.G.; van de Sluis, B.; Kirkland, J.L.; van Deursen, J.M. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479, 232–236. [Google Scholar] [CrossRef]
  7. Liu, Y.; Johnson, S.M.; Fedoriw, Y.; Rogers, A.B.; Yuan, H.; Krishnamurthy, J.; Sharpless, N.E. Expression of p16(INK4a) prevents cancer and promotes aging in lymphocytes. Blood 2011, 117, 3257–3267. [Google Scholar] [CrossRef]
  8. Rodier, F.; Campisi, J. Four faces of cellular senescence. J. Cell Biol. 2011, 192, 547–556. [Google Scholar] [CrossRef]
  9. Sharpless, N.E.; DePinho, R.A. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 2007, 8, 703–713. [Google Scholar] [CrossRef]
  10. Dodig, S.; Cepelak, I.; Pavic, I. Hallmarks of senescence and aging. Biochem. Med. (Zagreb) 2019, 29, 030501. [Google Scholar] [CrossRef]
  11. McHugh, D.; Gil, J. Senescence and aging: Causes, consequences, and therapeutic avenues. J. Cell Biol. 2018, 217, 65–77. [Google Scholar] [CrossRef] [PubMed]
  12. Rentscher, K.E.; Carroll, J.E.; Repetti, R.L.; Cole, S.W.; Reynolds, B.M.; Robles, T.F. Chronic stress exposure and daily stress appraisals relate to biological aging marker p16(INK4a). Psychoneuroendocrinology 2019, 102, 139–148. [Google Scholar] [CrossRef] [PubMed]
  13. Liu, Y.; Sanoff, H.K.; Cho, H.; Burd, C.E.; Torrice, C.; Ibrahim, J.G.; Thomas, N.E.; Sharpless, N.E. Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. Aging Cell 2009, 8, 439–448. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Nelson, J.A.; Krishnamurthy, J.; Menezes, P.; Liu, Y.; Hudgens, M.G.; Sharpless, N.E.; Eron, J.J., Jr. Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy. Aging Cell 2012, 11, 916–918. [Google Scholar] [CrossRef] [Green Version]
  15. LaPak, K.M.; Burd, C.E. The molecular balancing act of p16(INK4a) in cancer and aging. Mol. Cancer Res. 2014, 12, 167–183. [Google Scholar] [CrossRef] [Green Version]
  16. Shen, J.; Hernandez, D.; Ye, Y.; Wu, X.; Chow, W.H.; Zhao, H. Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study. Sci Rep. 2019, 9, 9989. [Google Scholar] [CrossRef]
  17. Shen, J.; Hernandez, D.; McNeill, L.H.; Chow, W.H.; Zhao, H. Associations of serum CRP levels with demographics, health behaviors, and risk of cancer among the Mexican American Mano A Mano Cohort. Cancer Epidemiol. 2019, 60, 1–7. [Google Scholar] [CrossRef]
  18. Diez Roux, A.V.; Ranjit, N.; Jenny, N.S.; Shea, S.; Cushman, M.; Fitzpatrick, A.; Seeman, T. Race/ethnicity and telomere length in the Multi-Ethnic Study of Atherosclerosis. Aging Cell 2009, 8, 251–257. [Google Scholar] [CrossRef] [Green Version]
  19. Rewak, M.; Buka, S.; Prescott, J.; De Vivo, I.; Loucks, E.B.; Kawachi, I.; Non, A.L.; Kubzansky, L.D. Race-related health disparities and biological aging: Does rate of telomere shortening differ across blacks and whites? Biol. Psychol. 2014, 99, 92–99. [Google Scholar] [CrossRef] [Green Version]
  20. Brown, L.; Needham, B.; Ailshire, J. Telomere Length Among Older, U.S. Adults: Differences by Race/Ethnicity, Gender, and Age. J. Aging Health 2017, 29, 1350–1366. [Google Scholar] [CrossRef]
  21. Hamad, R.; Tuljapurkar, S.; Rehkopf, D.H. Racial and Socioeconomic Variation in Genetic Markers of Telomere Length: A Cross-Sectional Study of U.S. Older Adults. EBioMedicine 2016, 11, 296–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Gee, G.C.; Hing, A.; Mohammed, S.; Tabor, D.C.; Williams, D.R. Racism and the Life Course: Taking Time Seriously. Am. J. Public Health 2019, 109, S43–S47. [Google Scholar] [CrossRef] [PubMed]
  23. Bailey, Z.D.; Krieger, N.; Agenor, M.; Graves, J.; Linos, N.; Bassett, M.T. Structural racism and health inequities in the USA: Evidence and interventions. Lancet 2017, 389, 1453–1463. [Google Scholar] [CrossRef]
  24. Krieger, N.; Smith, K.; Naishadham, D.; Hartman, C.; Barbeau, E.M. Experiences of discrimination: Validity and reliability of a self-report measure for population health research on racism and health. Soc. Sci. Med. 2005, 61, 1576–1596. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Plascak, J.J.; Hohl, B.; Barrington, W.E.; Beresford, S.A. Perceived neighborhood disorder, racial-ethnic discrimination and leading risk factors for chronic disease among women: California Behavioral Risk Factor Surveillance System, 2013. SSM Popul. Health 2018, 5, 227–238. [Google Scholar] [CrossRef] [PubMed]
  26. Seeman, T.; Epel, E.; Gruenewald, T.; Karlamangla, A.; McEwen, B.S. Socio-economic differentials in peripheral biology: Cumulative allostatic load. Ann. N. Y. Acad. Sci. 2010, 1186, 223–239. [Google Scholar] [CrossRef]
  27. Cottage, C.T.; Peterson, N.; Kearley, J.; Berlin, A.; Xiong, X.; Huntley, A.; Zhao, W.; Brown, C.; Migneault, A.; Zerrouki, K.; et al. Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice. Commun. Biol. 2019, 2, 307. [Google Scholar] [CrossRef] [Green Version]
  28. Tsygankov, D.; Liu, Y.; Sanoff, H.K.; Sharpless, N.E.; Elston, T.C. A quantitative model for age-dependent expression of the p16INK4a tumor suppressor. Proc. Natl. Acad. Sci. USA 2009, 106, 16562–16567. [Google Scholar] [CrossRef] [Green Version]
  29. Gorin, S.S. Theory, measurement, and controversy in positive psychology, health psychology, and cancer: Basics and next steps. Ann. Behav. Med. 2010, 39, 43–47. [Google Scholar] [CrossRef]
  30. Weinberger, M.I.; Bruce, M.L.; Roth, A.J.; Breitbart, W.; Nelson, C.J. Depression and barriers to mental health care in older cancer patients. Int. J. Geriatr. Psychiatry 2011, 26, 21–26. [Google Scholar] [CrossRef] [Green Version]
  31. Wallace, E.; Hinds, A.; Campbell, H.; Mackay, J.; Cetnarskyj, R.; Porteous, M.E. A cross-sectional survey to estimate the prevalence of family history of colorectal, breast and ovarian cancer in a Scottish general practice population. Br. J. Cancer. 2004, 91, 1575–1579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Haber, G.; Ahmed, N.U.; Pekovic, V. Family history of cancer and its association with breast cancer risk perception and repeat mammography. Am. J. Public Health 2012, 102, 2322–2329. [Google Scholar] [CrossRef] [PubMed]
  33. Casellas-Grau, A.; Font, A.; Vives, J. Positive psychology interventions in breast cancer. A systematic review. Psychooncology 2014, 23, 9–19. [Google Scholar] [CrossRef]
  34. Chamie, K.; Saigal, C.S.; Litwin, M.S. Patients and solipsism: The psychology of decision making for prostate cancer treatment. Urol. Oncol. 2011, 29, 233–234. [Google Scholar] [CrossRef] [PubMed]
  35. Lee, S.; Schmitt, C.A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 2019, 21, 94–101. [Google Scholar] [CrossRef]
  36. Campo-Trapero, J.; Cano-Sanchez, J.; Palacios-Sanchez, B.; Llamas-Martinez, S.; Lo Muzio, L.; Bascones-Martinez, A. Cellular senescence in oral cancer and precancer and treatment implications: A review. Acta Oncol. 2008, 47, 1464–1474. [Google Scholar] [CrossRef]
  37. Herranz, N.; Gil, J. Mechanisms and functions of cellular senescence. J. Clin. Invest. 2018, 128, 1238–1246. [Google Scholar] [CrossRef]
  38. Inoue, K.; Fry, E.A. Aberrant expression of p16(INK4a) in human cancers—A new biomarker? Cancer Rep. Rev. 2018, 2. [Google Scholar] [CrossRef] [Green Version]
Table 1. Distribution of characteristics among participants by case–control status.
Table 1. Distribution of characteristics among participants by case–control status.
VariableControls, n (%)Cases, n (%)p Value
Overall324 (100)352 (100)
P16INK4a, mean (SD)3.27 (2.31)4.58 (2.47)<0.001
Age (by median in controls)
<51 years174 (53.70)152 (43.18)
≥51 years150 (46.30)200 (56.82)0.006
Race
White192 (59.26)212 (60.23)
Black89 (27.47)96 (27.27)
Hispanic 43 (13.27)44 (12.50)0.948
Education
<college129 (39.81)163 (46.31)
≥some college195 (60.19)189 (53.69)0.089
Marital status
Married or living together171 (52.78)184 (52.27)
Other153 (47.22)168 (47.73)0.896
Income
<USD 50,000133 (41.05)170 (48.30)
≥USD 50,000191 (58.95)182 (51.70)0.058
BMI category
Underweight/normal weight90 (27.78)82 (23.30)
Overweight149 (45.99)167 (47.44)
Obese85 (26.23)103 (29.26)0.374
Family history of cancer
No295 (91.05)287 (81.53)
Yes29 (8.95)65 (18.47)<0.001
Smoking status
Never173 (53.40)166 (47.16)
Former92 (28.40)108 (30.68)
Current59 (18.21)78 (22.16)0.234
Alcohol drinking
Never158 (48.77)153 (43.47)
Former69 (21.30)87 (24.72)
Current97 (29.94)112 (31.82)0.354
Physical activity
Low172 (53.09)180 (51.14)
Medium or high152 (46.91)172 (48.86)0.612
Sitting time
<4 h/day159 (49.07)162 (46.02)
≥4 h/day165 (50.93)190 (53.98)0.427
Tumor subtype
ER+ 268 (76.14)
ER− 84 (23.86)
Tumor stage
I/II 282 (80.11)
III 70 (19.89)
Tumor grade
Well/moderate differentiated 269 (76.42)
Poorly differentiated 83 (23.58)
Tumor size
<2 cm 277 (78.69)
≥2 cm 75 (21.31)
Table 2. Comparison of P16INK4a expression by demographics and tumor characteristics.
Table 2. Comparison of P16INK4a expression by demographics and tumor characteristics.
VariableMean (SD)p Value *Mean (SD)p Value *p Value $
ControlsCases
Age at enrollment, years (by median in control)
<51 years2.02 (1.79)1.0002.99 (1.78)1.000<0.001
≥51 years4.72 (2.76)<0.0015.79 (2.57)<0.001<0.001
Race
White3.08 (2.12)1.0004.22 (2.93)1.000<0.001
Black3.79 (3.01)0.0215.18 (3.79)0.0130.008
Hispanic3.04 (2.55)0.9255.01 (4.76)0.1800.021
Education
<College3.11 (2.50)1.0004.39 (2.88)1.000<0.001
≥Some college3.38 (2.14)0.3274.74 (2.46)0.204<0.001
Marital status
Married or living together3.06 (2.48)1.0004.27 (2.73)1.000<0.001
Others3.50 (2.61)0.1344.92 (2.77)0.029<0.001
Income
<USD 50,0003.34 (2.58)1.0004.93 (2.39)1.000<0.001
≥USD 50,0003.22 (2.49)0.6624.25 (2.28)0.009<0.001
BMI category
Under/normal weight3.22 (2.71)1.0004.39 (2.56)1.0000.006
Overweight3.30 (2.44)0.8264.48 (2.31)0.790<0.001
Obese3.27 (2.82)0.9114.89 (2.72)0.229<0.001
Family history of cancer
No3.11 (2.19)1.0004.29 (2.31)1.000<0.001
Yes4.90 (3.21)<0.0015.86 (3.82)<0.0010.280
Smoking status
Never3.20 (2.56)1.0004.33 (2.82)1.000<0.001
Former3.25 (3.26)0.9044.51 (2.62)0.6120.007
Current3.51 (2.62)0.4715.21 (3.39)0.0390.006
Alcohol drinking
Never3.18 (2.37)1.0004.29 (2.87)1.000<0.001
Former3.26 (3.02)0.8434.60 (3.13)0.5030.011
Current3.42 (3.16)0.5074.96 (2.79)0.068<0.001
Physical activity
Low3.44 (2.32)1.0004.77 (2.31)1.000<0.001
Medium or high3.08 (2.47)0.1894.38 (2.37)0.124<0.001
Sitting time
<4 h/day3.12 (2.56)1.0004.40 (2.84)1.000<0.001
≥4 h/day3.41 (2.49)0.3264.73 (2.55)0.279<0.001
Tumor subtype
ER+ 4.47 (2.26)1.000
ER− 4.93 (4.01)0.198
Tumor stage
I/II 4.55 (2.38)1.000
III 4.70 (3.89)0.714
Tumor grade
Well/moderate differentiated 4.32 (2.19)1.000
Poorly differentiated 5.42 (3.47)0.002
Tumor size
<2 cm 4.41 (2.29)1.000
≥2 cm 5.21 (3.55)0.025
*: Comparison within case and control groups, adjusted by age if appropriate, $: comparison between case and control groups, adjusted by age if appropriate.
Table 3. Association between P16INK4a expression and breast cancer risk in the case–control study.
Table 3. Association between P16INK4a expression and breast cancer risk in the case–control study.
p16INK4a ExpressionControls, N (%)Cases, N (%)Unadj. OR (95%CI)p ValueAdj. OR (95% CI) *p Value
Continuous (0.1% unit)324 (100)352 (100)1.40 (1.21, 1.68)<0.0011.36 (1.19, 1.58)<0.001
By 75% in controls
<4.76244 (75.31)213 (60.51)Reference Reference
≥4.7680 (24.69)139 (39.49)1.99 (1.41, 2.81)<0.0011.81 (1.29–2.45)<0.001
By quartile in the controls
1st 80 (24.69)52 (14.77)Reference Reference
2nd 82 (25.31)75 (21.31)1.41 (0.86, 2.31)0.1531.33 (0.80, 2.14)0.194
3rd 79 (24.38)86 (24.43)1.67 (1.03, 2.74)0.0291.56 (0.94–2.66)0.098
4th 83 (25.62)139 (39.49)2.58 (1.62, 4.11)0.0102.46 (1.57–4.04)<0.001
p for trend <0.001 <0.001
* Adjusted by age, race, education, marital, income, BMI category, family history of cancer, smoking status, alcohol status, physical activity, and sitting time.
Table 4. Validation of the association using pre-diagnostic PBMCs.
Table 4. Validation of the association using pre-diagnostic PBMCs.
P16INK4a ExpressionControls, N = 47Cases, N = 48 p ValueUnadj. OR (95%CI)p ValueAdj, OR (95% CI) *p Value
Continuous, Mean (SD)3.41 (2.99)4.39 (3.08)0.0371.29 (1.02, 2.72)0.0471.28 (0.98, 2.97)0.053
* Adjusted by age, education, marital, income, BMI category, family history of cancer, smoking status, alcohol status, physical activity, and sitting.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shen, J.; Song, R.; Fuemmeler, B.F.; McGuire, K.P.; Chow, W.-H.; Zhao, H. Biological Aging Marker p16INK4a in T Cells and Breast Cancer Risk. Cancers 2020, 12, 3122. https://doi.org/10.3390/cancers12113122

AMA Style

Shen J, Song R, Fuemmeler BF, McGuire KP, Chow W-H, Zhao H. Biological Aging Marker p16INK4a in T Cells and Breast Cancer Risk. Cancers. 2020; 12(11):3122. https://doi.org/10.3390/cancers12113122

Chicago/Turabian Style

Shen, Jie, Renduo Song, Bernard F. Fuemmeler, Kandace P. McGuire, Wong-Ho Chow, and Hua Zhao. 2020. "Biological Aging Marker p16INK4a in T Cells and Breast Cancer Risk" Cancers 12, no. 11: 3122. https://doi.org/10.3390/cancers12113122

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop